Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Zimran

Showing results (21-30 of 135) with videos related to

Pageof 14
Sort By:
The Israel Medical Association Journal : IMAJ|May 11, 2000
Type IIIc Gaucher disease and acrodysostosisA Abrahamov, D Elstein, A Zimran
British Journal of Haematology|May 1, 1988
The in vivo ageing of red cell enzymes: direct evidence of biphasic decay from polycythaemic rabbits with reticulocytosisA Zimran, S Torem, E Beutler
Nephron|January 1, 1988
Reduced incidence of hyperkalemia and azotemia in patients receiving sulindac compared with indomethacinG Nesher, A Zimran, C Hershko
Harefuah|August 1, 1997
[Large scale screening for Gaucher's disease in Israel--a position paper by the National Gaucher Committee of the Ministry of Health]A Zimran, R Zaizov, J Zlotogora
Israel Journal of Medical Sciences|November 1, 1994
Use of the APACHE II severity score in an Israeli GICUM Hersch, D Elstein, A Zimran
Acta Neurologica Scandinavica|March 23, 2007
Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease?A Halperin, D Elstein, A Zimran
American Journal of Human Genetics|May 1, 1990
Linkage of the PvuII polymorphism with the common Jewish mutation for Gaucher diseaseA Zimran, T Gelbart, E Beutler
Clinical Genetics|October 27, 1998
Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher diseaseD Elstein, A Abrahamov, A Zimran
American Journal of Clinical Pathology|June 1, 1990
Detection of the 1226 (Jewish) mutation for Gaucher's disease by color PCR. A means for studying the gene frequency of the disorderA Zimran, W C Kuhl, E Beutler
Harefuah|February 1, 1988
[Neisseria infections in hereditary complement deficiency]M R Kramer, A Zimran, C Hershko
Pageof 14

Showing results (21-30 of 135) with videos related to

Sort By:
Pageof 14
The Israel Medical Association Journal : IMAJ|May 11, 2000
Type IIIc Gaucher disease and acrodysostosisA Abrahamov, D Elstein, A Zimran
British Journal of Haematology|May 1, 1988
The in vivo ageing of red cell enzymes: direct evidence of biphasic decay from polycythaemic rabbits with reticulocytosisA Zimran, S Torem, E Beutler
Nephron|January 1, 1988
Reduced incidence of hyperkalemia and azotemia in patients receiving sulindac compared with indomethacinG Nesher, A Zimran, C Hershko
Harefuah|August 1, 1997
[Large scale screening for Gaucher's disease in Israel--a position paper by the National Gaucher Committee of the Ministry of Health]A Zimran, R Zaizov, J Zlotogora
Israel Journal of Medical Sciences|November 1, 1994
Use of the APACHE II severity score in an Israeli GICUM Hersch, D Elstein, A Zimran
Acta Neurologica Scandinavica|March 23, 2007
Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease?A Halperin, D Elstein, A Zimran
American Journal of Human Genetics|May 1, 1990
Linkage of the PvuII polymorphism with the common Jewish mutation for Gaucher diseaseA Zimran, T Gelbart, E Beutler
Clinical Genetics|October 27, 1998
Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher diseaseD Elstein, A Abrahamov, A Zimran
American Journal of Clinical Pathology|June 1, 1990
Detection of the 1226 (Jewish) mutation for Gaucher's disease by color PCR. A means for studying the gene frequency of the disorderA Zimran, W C Kuhl, E Beutler
Harefuah|February 1, 1988
[Neisseria infections in hereditary complement deficiency]M R Kramer, A Zimran, C Hershko
Pageof 14